38.39
price down icon1.82%   -0.71
after-market Dopo l'orario di chiusura: 38.12 -0.27 -0.70%
loading

Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie

pulisher
Apr 15, 2025

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM): Are Analysts Optimistic? - simplywall.st

Apr 15, 2025
pulisher
Apr 14, 2025

FDA Approves Mirum Pharmaceuticals’ Drug For Rare Liver Disease Patients In Tablet Form: Retail Stays Bullish - MSN

Apr 14, 2025
pulisher
Apr 14, 2025

Mirum stock in focus after FDA nod for Livmarli tablet (MIRM) - Seeking Alpha

Apr 14, 2025
pulisher
Apr 14, 2025

Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Mirum'S Livmarli Now FDA Approved In Tablet Formulation - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire

Apr 14, 2025
pulisher
Apr 14, 2025

FDA Green Lights Game-Changing Tablet Version of Rare Liver Disease Drug LIVMARLI - Stock Titan

Apr 14, 2025
pulisher
Apr 10, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Apr 10, 2025
pulisher
Apr 10, 2025

Mirum Pharma Expands Team with Major Equity Awards Package for Key New Talent - Stock Titan

Apr 10, 2025
pulisher
Apr 02, 2025

Alagille Syndrome Market Growth to Accelerate in Forecast - openPR.com

Apr 02, 2025
pulisher
Apr 01, 2025

(MIRM) Investment Report - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 28, 2025

Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 27, 2025

Mirum Pharmaceuticals Says Livmarli Approved in Japan for Pruritus - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

LIVMARLI Now Approved In Japan For ALGS And PFIC - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

LIVMARLI Now Approved in Japan for ALGS and PFIC - Business Wire

Mar 27, 2025
pulisher
Mar 24, 2025

Mirum Pharmaceuticals: Set Fair For Share Price MomentumReversing My Sell Call (MIRM) - Seeking Alpha

Mar 24, 2025
pulisher
Mar 24, 2025

Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (NASDAQ:MIRM) - Seeking Alpha

Mar 24, 2025
pulisher
Mar 24, 2025

Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st

Mar 24, 2025
pulisher
Mar 22, 2025

(MIRM) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Mar 22, 2025
pulisher
Mar 21, 2025

Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st

Mar 21, 2025
pulisher
Mar 20, 2025

Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock By Investing.com - Investing.com Australia

Mar 20, 2025
pulisher
Mar 20, 2025

Mirum’s Rare Disease Strategy: A Blueprint For Sustainable Growth - insights.citeline.com

Mar 20, 2025
pulisher
Mar 19, 2025

Mirum Pharmaceuticals SVP Jolanda Howe sells $107,342 in stock - Investing.com India

Mar 19, 2025
pulisher
Mar 18, 2025

Mirum Pharmaceuticals CEO sells $1.2 million in stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Mirum Pharmaceuticals president sells $348k in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Mirum Pharmaceuticals CEO sells $1.2 million in stock - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mirum Pharmaceuticals’ SVP Jolanda Howe sells $2.4 million in stock By Investing.com - Investing.com UK

Mar 18, 2025
pulisher
Mar 18, 2025

Mirum Pharmaceuticals director Heron buys $24,214 in stock By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

Mirum Pharmaceuticals director Heron buys $24,214 in stock - Investing.com India

Mar 18, 2025
pulisher
Mar 17, 2025

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older - Business Wire

Mar 17, 2025
pulisher
Mar 13, 2025

Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Mirum Pharmaceuticals director Heron buys $99,517 in stock - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Mirum Pharmaceuticals’ SWOT analysis: FDA nod boosts rare disease stock By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 12, 2025

Mirum Pharmaceuticals director Heron buys $99,517 in stock By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Mirum Pharmaceuticals at Leerink Conference: Growth in Rare Diseases By Investing.com - Investing.com Canada

Mar 12, 2025
pulisher
Mar 11, 2025

(MIRM) Proactive Strategies - Stock Traders Daily

Mar 11, 2025
pulisher
Mar 10, 2025

Mirum Pharmaceuticals Strengthens Growth Strategy with Strategic New Hires and Equity Incentives - StockTitan

Mar 10, 2025
pulisher
Mar 10, 2025

Mirum Pharmaceuticals director Heron buys $83,661 in stock By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Mirum Pharmaceuticals director Heron buys $83,661 in stock - Investing.com India

Mar 10, 2025
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Capitalizzazione:     |  Volume (24 ore):